Vermillion (VRML) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Vermillion Reports Third Quarter 2015 Financial Results and Business Update
November 12, 2015 8:01 AM ESTAUSTIN, Texas, Nov. 12, 2015 /PRNewswire/ --Â Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported financial results for the third quarter ended September 30, 2015 and provided a business update.
Valerie Palmieri, President and CEO of Vermillion, Inc., stated, "The third quarter marked a number of accomplishments and we are on track with our 2015 milestone plan. The submission of our second-generation OVA1® test, Overa®, continues to progress with the FDA. On the commercial front in the US, we now have positive medical policy with CareFirst Blue... More
